Skip to content
Research/Metabolic Optimization/SGLT2 Inhibitor

SGLT2 Inhibitor

SGLT2 inhibitors are a class of medications that lower blood sugar by preventing the kidneys from reabsorbing glucose, leading to its excretion in urine. They are primarily used to manage type 2 diabetes but have shown potential benefits for cardiovascular health and weight management, making them relevant for longevity and health optimization.

Intelligence Profile

Research Papers

Research on SGLT2 inhibitors has grown significantly, with studies highlighting their benefits in various medical conditions.

  1. Heart Failure with Preserved Ejection Fraction (HFpEF): A retrospective study published in Frontiers in Cardiovascular Medicine demonstrated that long-term SGLT2 inhibitor therapy improved myocardial strain and diastolic function, linking these improvements to reduced myocardial fibrosis. This suggests potential benefits in heart failure management.

  2. Type 2 Diabetes: A cross-sectional study in Diabetes, Obesity & Metabolism evaluated SGLT2 inhibitor use in England, focusing on how well healthcare providers are adopting NICE guidelines. Additionally, a multinational cohort study in Diabetes & Metabolism found that SGLT2 inhibitors might be more effective in reducing all-cause mortality compared to dipeptidyl peptidase-4 inhibitors.

  3. Chronic Kidney Disease (CKD): Research in Clinical and Experimental Nephrology explored the interaction between SGLT2 inhibitors and prior angiotensin receptor-neprilysin inhibitor use, particularly regarding initial eGFR changes. Moreover, Frontiers in Pharmacology conducted a cost-utility analysis of using both finerenone and empagliflozin for type 2 diabetes with CKD.

  4. Cognitive Function: Frontiers in Pharmacology discussed how dapagliflozin may influence cognitive impairment, providing insights into its pharmacological mechanisms and potential future applications.

  5. Cardiovascular and Renal Outcomes: A meta-analysis in JACC. Heart Failure combined data from DAPA-HF, DELIVER, and DAPA ACT HF-TIMI 68 trials, reinforcing dapagliflozin's role in managing heart failure across the care spectrum. Another meta-analysis in Diabetes Research and Clinical Practice highlighted canagliflozin's effects on end-stage kidney disease and cardiovascular mortality in older adults, using data from the CANVAS and CREDENCE trials.

  6. Ongoing Clinical Trials: Several trials are investigating SGLT2 inhibitors in diverse scenarios:

    • A Phase 3 trial (NCT05879276) is assessing empagliflozin's effects in cardiogenic shock patients.
    • An early-phase trial (NCT04780438) is examining dapagliflozin in preventing atrial fibrillation recurrence.
    • A Phase 4 study (NCT04127084) is looking at SGLT2 inhibitors' effects on albuminuria levels in type 2 diabetes.
    • A completed Phase 4 trial (NCT05621551) evaluated dapagliflozin therapy in cardiac surgery.

Overall, evidence supports SGLT2 inhibitors in improving heart failure, diabetes management, kidney function, and potentially cognitive health, though more research is needed in some areas.

Disclaimer: This summary is for informational purposes only and is not a substitute for professional medical advice.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.